Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

As Sanofi ex­pands the reach of its block­buster Dupix­ent, the French Big Phar­ma is look­ing to go fur­ther down­stream in the IL-13 and IL-4 space with more in­flam­ma­tion and im­munol­o­gy drugs. It’s dol­ing out $125 mil­lion in up­front pay­ments to Re­cludix Phar­ma to do so.

This is Sanofi’s sec­ond pre­clin­i­cal col­lab­o­ra­tion of the week, fol­low­ing a sick­le cell dis­ease tie-up with Scribe Ther­a­peu­tics. It will work with San Diego-based Re­cludix on in­hibitors of STAT6, a tran­scrip­tion fac­tor that hits the ac­tiv­i­ty of key cy­tokines dri­ving type 2 in­flam­ma­to­ry dis­eases — name­ly IL-13 and IL-4, which are tar­get­ed by Sanofi and Re­gen­eron’s Dupix­ent.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER